Diagnosis and Management of Dystonia

CONTINUUM Lifelong Learning in Neurology

Volumn 22, Issue 4,MovementDisorders, 2016, Pages 1227-1245

  Shanker, Vicki ^a   Bressman, Susan B ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; BOTULINUM TOXIN; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; LEVODOPA; NEUROTOXIN; BACLOFEN; CLONAZEPAM; DIAZEPAM; TETRABENAZINE; TRIHEXYPHENIDYL; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ATP1A3 PROTEIN, HUMAN;

ATP1A3 GENE; BRAIN DEPTH STIMULATION; DISEASE CLASSIFICATION; DYSTONIA; GENE; GENE MUTATION; GENETIC SCREENING; HUMAN; PHENOMENOLOGY; PHENOTYPE; PHYSICAL EXAMINATION; REVIEW; CLINICAL FEATURE; NEUROSURGERY; PATHOGENESIS; PATIENT ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); DENERVATION; DISEASE MANAGEMENT; GENETICS; MUTATION; PROCEDURES;

DEEP BRAIN STIMULATION; DENERVATION; DISEASE MANAGEMENT; DYSTONIA; HUMANS; MUTATION; NEUROTOXINS; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 84982952346     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/CON.0000000000000352     Document Type: Review

References (63)

1. Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: A consensus update. Mov Disord 2013;28(7): 863-873. doi:10.1002/mds.25475.
2. Deuschl G. Dystonic tremor. Rev Neurol (Paris) 2003;159(10 pt 1):900-905.
3. Greene PE, Bressman S. Exteroceptive and interoceptive stimuli in dystonia. Mov Disord 1998;13(3):549-551. doi:10.1002/mds. 870130329.
4. Liang CC, Tanabe LM, Jou S, et al. TorsinA hypofunction causes abnormal twisting movements and sensorimotor circuit neurodegeneration. J Clin Invest 2014;124(7): 3080-3092. doi:10.1172/JCI72830.
5. Dufke C, Hauser AK, Sturm M, et al. Mutations in CIZ1 are not a major cause for dystonia in Germany. Mov Disord 2015;30(5): 740-743. doi:10.1002/mds.26198.
6. Ma L, Chen R, Wang L, et al. No mutations in CIZ1 in twelve adult-onset primary cervical dystonia families. Mov Disord 2013;28(13): 1899-1901. doi:10.1002/mds.25542.
7. Charlesworth G, Plagnol V, Holmström KM, et al. Mutations in ANO3 cause dominant craniocervical dystonia: ion channel implicated in pathogenesis. Am J Hum Genet 2012;91(6): 1041-1050. doi:10.1016/j.ajhg.2012.10.024.
8. Fuchs T, Saunders-Pullman R, Masuho I, et al. Mutations in GNAL cause primary torsion dystonia. Nat Genet 2013;45(1):88-92. doi:10.1038/ng.2496.
9. Balint B, Bhatia KP. Isolated and combined dystonia syndromesVan update on new genes and their phenotypes. Eur J Neurol 2015;22(4):610-617. doi:10.1111/ene.12650.
10. Wijemanne S, Jankovic J. Dopa-responsive dystoniaVclinical and genetic heterogeneity. Nat Rev Neurol 2015;11(7):414-424. doi:10.1038/nrneurol.2015.86.
11. Sweney MT, Newcomb TM, Swoboda KJ. The expanding spectrum of neurological phenotypes in children with ATP1A3mutations, Alternating Hemiplegia of Childhood, Rapid-onset Dystonia-Parkinsonism, CAPOS and beyond. Pediatr Neurol 2015;52(1):56-64. doi:10.1016/j.pediatrneurol.2014.09.015.
12. Peall KJ, Dijk JM, Saunders-Pullman R, et al. Psychiatric disorders, myoclonus dystonia and SGCE: An international study. Ann Clin Transl Neuro 2016;3(1):4-11. doi:10.1002/acn3.263.
13. Groen JL, Andrade A, Ritz K, et al. CACNA1B mutation is linked to unique myoclonus-dystonia syndrome. Hum Mol Genet 2015;24(4): 987-993. doi:10.1093/hmg/ddu513.
14. Wang JL, Cao L, Li XH, et al. Identification of PRRT2 as the causative gene of paroxysmal kinesigenic dyskinesias. Brain 2011;134(pt 12): 3493-3501. doi:10.1093/brain/awr289.
15. ChenGH. Five cases of paroxysmal kinesigenic dyskinesia by genetic diagnosis. Exp Ther Med 2015;9(3):909-912. doi:10.3892/etm.2014.2155.
16. Suls A, Dedeken P, Goffin K, et al. Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter GLUT1. Brain 2008;131(pt 7): 1831-1844. doi:10.1093/brain/awn113.
17. Charlesworth G, Bhatia KP, Wood NW. The genetics of dystonia: new twists in an old tale. Brain 2013;136(pt 7):2017-2037. doi:10.1093/brain/awt138.
18. Peckham EL, Lopez G, Shamim EA, et al. Clinical features of patients with blepharospasm: A report of 240 patients. Eur J Neurol 2011;18(3):382-386. doi:10.1111/j.1468-1331. 2010.03161.x.
19. Defazio G, Hallett M, Jinnah HA, Berardelli A. Development and validation of a clinical guideline for diagnosing blepharospasm. Neurology 2013;81(3):236-240. doi:10.1212/WNL.0b013e31829bfdf6.
20. Payne S, Tisch S, Cole I, et al. The clinical spectrum of laryngeal dystonia includes dystonic cough: observations of a large series. Mov Disord 2014;29(6):729-735. doi:10.1002/mds.25865.
21. Grillone GA, Chan T. Laryngeal dystonia. Otolaryngol Clin North Am 2006;39(1): 87-100. doi:10.1007/s00415-014-7586-2.
22. Comella C, Bhatia K. An international survey of patients with cervical dystonia. J Neurol 2015;262(4):837-848. doi:10.1007/s00415-014-7586-2.
23. Charles PD, Adler CH, Stacy M, et al. Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol 2014;261(7):1309-1319. doi:10.1007/s00415-014-7343-6.
24. Louis ED, Dogu O. Isolated head tremor: part of the clinical spectrum of essential tremor? Data from population-based and clinic-based case samples. Mov Disord 2009;24(15): 2281-2285. doi:10.1002/mds.22777.
25. Schneider SA, Edwards MJ, Mir P, et al. Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord 2007;22(15): 2210-2215. doi:10.1002/mds.21685.
26. Hawthorne JM, Caley CF. Extrapyramidal reactions associated with serotonergic antidepressants. Ann Pharmacother 2015;49(10):1136-1152. doi:10.1177/1060028015594812.
27. Mehta SH, Morgan JC, SethiKD. Drug-induced movement disorders. Neurol Clin 2015;33(1): 153-174. doi:10.1016/j.ncl.2014.09.011.
28. Jinnah HA, Factor SA. Diagnosis and treatment of dystonia. Neurol Clin 2015;33(1):77-100. doi:10.1016/j.ncl.2014.09.002.
29. Thenganatt MA, Jankovic J. Treatment of dystonia. Neurotherapeutics 2014;11(1): 139-152. doi:10.1007/s13311-013-0231-4.
30. Hensman DJ, Bain PG. Levodopa can worsen tremor associated with dystonia. Mov Disord 2006;21(10):1778-1780. doi:10.1002/mds.21043.
31. Pozin I, Bdolah-AbramT, Ben-Pazi H. Levodopa does not improve function in individuals with dystonic cerebral palsy. J Child Neurol 2014; 29(4):534-537. doi:10.1177/0883073812473645.
32. Kenney C, Hunter C, Jankovic J. Long-Term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007;22(2):193-197. doi:10.1002/mds.21222.
33. Luciano AY, Jinnah HA, Pfeiffer RF, et al. Treatment of myoclonus-dystonia syndrome with tetrabenazine. Parkinsonism Relat Disord 2014;20(12):1423-1426. doi:10.1016/j.parkreldis.2014.09.029.
34. Illowsky Karp BI, Goldstein SR, Chen R, et al. An open trial of clozapine for dystonia. Mov Disord 1999;14(4):652-657. doi:10.1002/1531-8257(199907)14:4G652::AIDMDS101593.0. CO;2-G.
35. Gourzis P, Skokou M, Soubasi E, et al. Treatment of tardive dystonia induced by antipsychotics, old and new. Clin Neuropharmacol 2015;38(4):121-126. doi:10.1097/WNF.0000000000000086.
36. Burke RE, Fahn S, Marsden CD. Torsion dystonia: A double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 1986; 36(2):160-164. doi:10. 1212/WNL.36.2.160.
37. Fasano A, Bove F, Lang AE. The treatment of dystonic tremor: A systematic review. J Neurol Neurosurg Psychiatry 2014;85(7): 759-769. doi:10.1136/jnnp-2013-305532.
38. Kinugawa K, Vidailhet M, Clot F, et al. Myoclonus-dystonia: An update. Mov Disord 2009;24(4):479-489. doi:10.1002/mds.22425.
39. Strzelczyk A, Bürk K, Oertel WH. Treatment of paroxysmal dyskinesias. Expert Opin Pharmacother 2011;12(1):63-72. doi:10.1517/14656566.2010.513971.
40. Greene P, Shale H, Fahn S. Experience with high dosages of anticholinergic and other drugs in the treatment of torsion dystonia. Adv Neurol 1988;50:547-556.
41. Albright AL, Ferson SS. Intraventricular baclofen for dystonia: Techniques and outcomes. Clinical article. J Neurosurg Pediatr 2009;3(1): 11-14. doi:10.3171/2008.10.PEDS0847.
42. Frucht SJ, Bordelon Y, Houghton WH, Reardan D. A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders. Mov Disord 2005;20(10): 1330-1337. doi:10.1002/mds.20605.
43. Simonyan K, Frucht SJ. Long-Term effect of sodium oxybate (XyremA) in spasmodic dysphonia with vocal tremor. Tremor Other Hyperkinet Mov (N Y) 2013;3. doi:10.7916/D8CJ8C5S
44. Pfeiffer RF. Wilson disease. Continuum (Minneap Minn) 2016;22(4 Movement Disorders):1246-1261.
45. Walker TJ, Dayan SH. Comparison and overview of currently available neurotoxins. J Clin Aesthet Dermatol 2014;7(2):31-39.
46. Simpson DM, Hallet M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Neurology 2016;86(10):1818-1826. doi:10.1212/wnl. 0000000000002560.
47. Simpson DM, Blitzer A, Brashear A, et al; Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70(19): 1699-1706. doi:10.12/01.wnl.0000311389. 26145.95.48.
48. Hallett M, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon 2013;67:94-114. doi:10.1016/j.toxicon. 2012.12.004.
49. Ramirez-Castaneda J, Jankovic J. Long-Term efficacy and safety of botulinum toxin injections in dystonia. Toxins (Basel) 2013;5(2): 249-266. doi:10.3390/toxins5020249.
50. Grigoriu AI, Dinomais M, Rémy-Néris O, Brochard S. Impact of injection-guiding techniques on the effectiveness of botulinum toxin for the treatment of focal spasticity and dystonia: A systematic review. Arch Phys Med Rehabil 2015;96(11):2067-2078.e1. doi:10.1016/j.apmr.2015.05.002.
51. Delnooz CC, Veugen LC, Pasman JW, et al. The clinical utility of botulinum toxin injections targeted at the motor endplate zone in cervical dystonia. Eur J Neurol 2014;21(12):1486-e98. doi:10.1111/ene.12517.
52. Kupsch A, Benecke R, Müller J, et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006;355(19):1978-1990. doi:10.1056/NEJMoa063618.
53. Fox MD, Alterman RL. Brain stimulation for torsion dystonia. JAMA Neurol 2015;72(6): 713-719. doi:10.1001/jamaneurol.2015.51.
54. Brüggemann N, Kühn A, Schneider SA, et al. Short-And long-Term outcome of chronic pallidal neurostimulation in monogenic isolated dystonia. Neurology 2015;84(9): 895-903. doi:10.1212/WNL.0000000000001312.
55. Roze E, Vidailhet M, Hubsch C, et al. Pallidal stimulation for myoclonus-dystonia: Ten years outcome in two patients. Mov Disord 2015;30(6):871-872. doi:10.1002/mds.26215.
56. Nam TM, Cho KR, Youn J, et al. Deep brain stimulation in a dentatorubral-pallidoluyisian atrophy patient with myoclonic dystonia. J Clin Neurosci 2015;22(12):1976-1978. doi:10.1016/j.jocn.2015.04.010.
57. Patel AJ, Sarwar AI, Jankovic J, Viswanathan A. Bilateral pallidal deep brain stimulation for X-linked dystonia-parkinsonism. World Neurosurg 2014;82(1-2):241.e1-241.e4. doi:10.1016/j.wneu.2013.09.039.
58. Kupsch A, Tagliati M, Vidailhet M, et al. Early postoperative management of DBS in dystonia: programming, response to stimulation, adverse events, medication changes, evaluations, and troubleshooting. Mov Disord 2011;26(suppl 1):S37-S53. doi:10.1002/mds.23624.
59. Volkmann J, Mueller J, Deuschl G, et al. Pallidal neurostimulation in patients with medication-refractory cervical dystonia: A randomised, sham-controlled trial. Lancet Neurol 2014;13(9):875-884. doi:10.1016/S1474-4422(14)70143-7.
60. Kim JP, Chang WS, Park YS, Chang JW. Effects of relative low-frequency bilateral globus pallidus internus stimulation for treatment of cervical dystonia. Stereotact Funct Neurosurg 2012;90(1):30-36. doi:10.1159/000333839.
61. Owen T, GimenoH, Selway R, Lin JP. Cognitive function in children with primary dystonia before and after deep brain stimulation. Eur J Paediatr Neurol 2015;19(1):48-55. doi:10.1016/j.ejpn.2014.09.004.
62. Meoni S, Zurowski M, Lozano AM, et al. Long-Term neuropsychiatric outcomes after pallidal stimulation in primary and secondary dystonia. Neurology 2015;85(5):433-440. doi:10.1212/WNL.0000000000001811.
63. Bressman SB, de Leon D, Brin MF, et al. Inheritance of idiopathic torsion dystonia among Ashkenazi Jews. Adv Neurol 1988;50:45-56.